Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. (Q47557156)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 January 2018

Language	Label	Description	Also known as
English	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.	scientific article published on 5 January 2018

Statements

scholarly article

1 reference

Europe PubMed Central

3 February 2018

http://europepmc.org/abstract/MED/29310899

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. (English)

1 reference

Europe PubMed Central

3 February 2018

http://europepmc.org/abstract/MED/29310899

0 references

Francesco Castelli

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Pierre-Marie Girard

5

object named as

Pierre-Marie Girard

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Josep M Llibre

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Chien-Ching Hung

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Cynthia Brinson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lesley P Kahl

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Elizabeth A Blair

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Kostas Angelis

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Brian Wynne

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Kati Vandermeulen

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Mark Underwood

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Kim Smith

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Martin Gartland

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Michael Aboud

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

0 references

publication date

5 January 2018

1 reference

Europe PubMed Central

3 February 2018

http://europepmc.org/abstract/MED/29310899

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

391

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

839-849

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

10123

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychiatric Symptoms in Patients Receiving Dolutegravir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, o

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2933095-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)33095-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29310899%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47557156&oldid=1985471891"